Methods for treating allergic disorders using optically pure (-) cetirizine
US5698558A · kind A · utility
19Cited by
1References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 27, 1997 |
| Grant date | Dec 16, 1997 |
| Priority date | — |
| Expiry date | Jan 27, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.